AURO-TELMISARTAN TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

TELMISARTAN

可用日期:

AURO PHARMA INC

ATC代码:

C09CA07

INN（国际名称）:

TELMISARTAN

剂量:

40MG

药物剂型:

TABLET

组成:

TELMISARTAN 40MG

给药途径:

ORAL

每包单位数:

30/100/500

处方类型:

Prescription

治疗领域:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

產品總結:

Active ingredient group (AIG) number: 0138223001; AHFS:

授权状态:

APPROVED

授权日期:

2016-04-04

产品特点

AURO-TELMISARTAN Product Monograph
Page 1 of 39
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
AURO-TELMISARTAN
Telmisartan Tablets, USP
Tablets, 40 mg and 80 mg, Oral
Angiotensin II AT1 Receptor Blocker
Auro Pharma Inc.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada.
Date of Initial Authorization:
April 04, 2016
Date of Revision:
June 02, 2023
Submission Control Number: 270620
AURO-TELMISARTAN Product Monograph
Page 2 of 39
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
06/2023
7 WARNINGS AND PRECAUTIONS
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF
CONTENTS…………………………………………………………………………………………..…………………2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1 INDICATIONS
.....................................................................................................................
4
1.1
Pediatrics.......................................................................................................................
4
1.2 Geriatrics
.......................................................................................................................
4
2 CONTRAINDICATIONS
........................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................... 5
4 DOSAGE AND ADMINISTRATION
........................................................................................
5
4.1 Dosing Considerations
...................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
.............................................................. 5
4.4 Administration
.......................................................................................................